Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Security

ADARx Pharmaceuticals, Inc. Common Stock · ADRX

ADRXNASDAQCommon stockCurrentCIK 1802369Updated Oct 4, 2026

Company: ADARx Pharmaceuticals, Inc. →

ADRX price & chart

Provider market data

Loading TradingView…

NASDAQ:ADRX on TradingView ↗

TradingView · Data may be delayed

About the company

We are a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. We are focused on advancing and expanding our pipeline of highly potent, selective and durable siRNA therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. Our goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs. Our team is united by a shared vision to build a leading next-generation siRNA therapeutics company.

424B4 · 2026-09-28 · 0001193125-26-403094

Company description from the cited filing.

Offerings

Registration 333-298782

424B4 · 2026-09-28 · 0001193125-26-403094

Terms from the governing filing for this registration; not a claim that the offering is open today.

Gross proceeds
446250000.0
Net proceeds
415012500.0
Deal price
17.0
Shares
26250000
Offering price
$17.00
Ticker
ADRX

Registration 333-299119

S-1MEF · 2026-09-24 · 0001193125-26-401133

Terms from the governing filing for this registration; not a claim that the offering is open today.

Filing attachments

d903461dex107.htm · S-1/A · 2026-09-21

EX-10.7 7 d903461dex107.htm EX-10.7 EX-10.7 Exhibit 10.7 ADAR X P HARMACEUTICALS, I NC. N ON -E MPLOYEE D IRECTOR C OMPENSATION P OLICY Each member of the Board of Directors (the “Board”) of ADARx Pharmaceuticals, Inc. (the “Company”) who is not also serving as an employee of or consultant to the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) for his or…

S-1/A · 2026-09-21 · 0001193125-26-396007

Read attachment ↗
d903461dex41.htm · S-1/A · 2026-09-14

EX-4.1 2 d903461dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 INCORPORATED UNDER THE CUSIP XXXXXX XX X LAWS OF THE STATE SEE REVERSE FOR CERTAIN OF DELAWARE DEFINITIONS AND LEGENDS This certifies that BY: COUNTERSIGNED is the record holder of AND EQUINITI FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE, OF ADARX PHARMACEUTICALS, INC. TRUST transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this Certificate properly…

S-1/A · 2026-09-14 · 0001193125-26-390724

Read attachment ↗
d903461dex42.htm · S-1 · 2026-09-04

EX-4.2 6 d903461dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 2nd day of August, 2023, by and among ADARx Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”. RECITALS WHEREAS, certain of the Investors (the “Existing I…

S-1 · 2026-09-04 · 0001193125-26-383838

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.